Overview

• Sanofi SA has terminated its licensing agreement for Maze Therapeutics Inc.'s treatment for Pompe disease following a lawsuit by the Federal Trade Commission (FTC).
• The FTC sued to block the deal, arguing that the $755 million agreement would maintain Sanofi's monopoly over treatments for Pompe disease.
• Sanofi currently sells two FDA-approved treatments for Pompe disease, which are administered via lengthy, biweekly intravenous infusions and cost hundreds of thousands of dollars for an annual course of treatment.
• Maze's drug, MZE001, is an oral tablet taken twice daily and has completed Phase 1 development. It is expected to significantly reduce patients' treatment burden.
• Sanofi decided to terminate the agreement due to the delay associated with a long litigation, stating it would not be in the best interests of patients to contest this litigation.